Holsztynska E J, Waxman D J
Arch Biochem Biophys. 1987 Aug 1;256(2):543-59. doi: 10.1016/0003-9861(87)90612-6.
Cytochrome P-450 cholesterol 7 alpha-hydroxylase (P-450Ch7 alpha) catalyzes the first and rate-limiting step in the conversion of cholesterol to bile acids. Incubation of rat liver microsomes in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer resulted in a time-dependent deactivation of P-450Ch7 alpha which was markedly accelerated by the nonionic detergent Tween 80. Microsomal NADPH-cytochrome P-450 reductase and cytochrome P-450-dependent 7-ethoxycoumarin O-deethylase activities were unaffected under these conditions, evidencing the selectivity of the deactivation process for P-450Ch7 alpha. The rate (t 1/2 = 15-19 min at 37 degrees C) and maximal extent of P-450Ch7 alpha deactivation (greater than or equal to 90%) were both unaffected by the presence of cytosolic proteins and were also not dependent on the initial enzyme level, as shown using liver microsomes isolated from untreated, cholestyramine-fed, and xenobiotic-induced rats exhibiting an eight-fold range in P-450Ch7 alpha activity. Scavengers for reduced oxygen species were also without effect. P-450Ch7 alpha was stabilized some six- to sevenfold (t 1/2 = 94-143 min) by the phosphatase inhibitor NaF. Of a series of other phosphatase inhibitors examined, including, among others, EDTA, vanadate, and molybdate, only phosphate-containing compounds and the calmodulin antagonist trifluoperazine, and inhibitor of the Ca2+-calmodulin-dependent phosphatase calcineurin, effectively stabilized P-450Ch7 alpha. Modulation of P-450Ch7 alpha deactivation by these inhibitors generally paralleled their effects on isolated calcineurin. A variety of structurally diverse calmodulin antagonists examined were also found to effectively protect P-450Ch7 alpha from deactivation; these include calmidazolium and tamoxifen (IC50 = 25 to 50 microM), chlorpromazine, thioridazine, amitriptyline, imipramine, and the naphthalene sulfonamide compound W-7 (IC50 = 50 to 300 microM). Structure-activity analysis of several phenothiazines and their derivatives indicated that although little activity was exhibited by the sulfoxides, some protection was provided by the corresponding sulfones. On the basis of these observations, various models for the molecular basis of enzyme deactivation are considered, including the hypothesis that a calcineurin-like microsomal phosphatase mediates deactivation of this cytochrome P-450 enzyme.
细胞色素P-450胆固醇7α-羟化酶(P-450Ch7α)催化胆固醇转化为胆汁酸过程中的第一步且是限速步骤。在4-(2-羟乙基)-1-哌嗪乙烷磺酸缓冲液中孵育大鼠肝微粒体,会导致P-450Ch7α随时间失活,非离子去污剂吐温80会显著加速这种失活。在这些条件下,微粒体NADPH-细胞色素P-450还原酶和细胞色素P-450依赖性7-乙氧基香豆素O-脱乙基酶活性不受影响,证明了失活过程对P-450Ch7α的选择性。P-450Ch7α失活的速率(37℃时t1/2 = 15 - 19分钟)和最大程度(大于或等于90%)均不受胞质蛋白存在的影响,也不依赖于初始酶水平,从未处理、服用消胆胺和经异生素诱导的大鼠分离的肝微粒体中P-450Ch7α活性范围达八倍时的实验结果表明了这一点。活性氧清除剂也没有作用。磷酸酶抑制剂氟化钠使P-450Ch7α稳定了约六至七倍(t1/2 = 94 - 143分钟)。在一系列其他检测的磷酸酶抑制剂中,包括乙二胺四乙酸、钒酸盐和钼酸盐等,只有含磷化合物以及钙调蛋白拮抗剂三氟拉嗪(一种Ca2 + -钙调蛋白依赖性磷酸酶钙调神经磷酸酶的抑制剂)能有效稳定P-450Ch7α。这些抑制剂对P-450Ch7α失活的调节通常与其对分离的钙调神经磷酸酶的作用相似。还发现多种结构各异的钙调蛋白拮抗剂能有效保护P-450Ch7α不被失活;这些包括氯咪达唑和他莫昔芬(IC50 = 25至50 microM)、氯丙嗪、硫利达嗪、阿米替林、丙咪嗪以及萘磺酰胺化合物W - 7(IC50 = 50至300 microM)。对几种吩噻嗪及其衍生物的构效分析表明,虽然亚砜几乎没有活性,但相应的砜提供了一定保护。基于这些观察结果,考虑了酶失活分子基础的各种模型,包括一种类似钙调神经磷酸酶的微粒体磷酸酶介导这种细胞色素P-450酶失活的假说。